Comparative Study of Perioperative Cardiac Injury in Patients With Functional Adrenal Tumors

Study Purpose

The main goal of this study is to follow patients with functional adrenal tumors during the time before and after their surgery. The main questions it aims to answer are:

- What heart and blood pressure changes do patients with different types of adrenal tumors have before surgery? - What factors affect how the heart and blood pressure recover after surgery? - Do the heart and blood pressure conditions before surgery influence recovery and the risk of heart or brain problems after surgery? Patients will have heart ultrasound checks and health monitoring before and after surgery.

The results will help doctors choose the right medicines before surgery, better understand possible risks during the operation, and make safer treatment plans for patients with functional adrenal tumors.

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	No
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Observational [Patient Registry]
Eligible Ages	18 Years and Over
Gender	All

More Inclusion & Exclusion Criteria

Inclusion Criteria:

- Patients diagnosed in the Department of Urology, Peking University First Hospital with pheochromocytoma and paraganglioma (PPGL), primary aldosteronism (PA), or Cushing syndrome (CS); - Written informed consent obtained.

Exclusion Criteria:

- Patients with PPGL, PA, or CS who receive medication or conservative treatment and are not eligible for surgical resection; - Patients with communication disorders or severe physical impairments such as aphasia, or visual/hearing disabilities; - Patients with severe mental illness who cannot cooperate with the study; - Pregnant women or patients otherwise deemed unsuitable for participation by the investigators.

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT07182175
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	Peking University First Hospital
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	N/A
Principal Investigator Affiliation	N/A
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	Other
Overall Status	Enrolling by invitation
Countries	China
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	Primary Aldosteronism, Adrenal Tumor, Cushing s Syndrome, Pheochromocytoma/Paraganglioma (PPGL)

Arms & Interventions

Arms

: primary aldosteronism

: Cushing s Syndrome

: Pheochromocytoma/Paraganglioma (PPGL)

Interventions

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Peking University First Hospital, Beijing 1816670, China

Status

Address

Peking University First Hospital

Beijing 1816670, ,

Clinical Trial Finder